中草药治疗银屑病:来自11项高质量随机对照试验的证据
本定量研究系统检索多个数据库,纳入高质量随机对照试验,比较中草药与非中草药干预治疗银屑病的疗效与安全性。共1215例患者参与,中草药组PASI评分显著低于安慰剂组,PASI-60和PASI-75到达率及有效率更高,DLQI改善更明显;瘙痒严重程度、复发率和不良事件比例与安慰剂组相似。结论认为中草药对银屑病安全有效且对生活质量有积极影响,但不能完全消除皮损、改善瘙痒严重程度或降低复发率。
要点
- 中草药组PASI评分显著低于安慰剂组(MD -4.02,95%CI -6.71至-1.34,p=0.003)。
- 中草药组PASI-75到达率显著高于安慰剂组(RR 9.87,95%CI 3.11至31.31,p=0.0001)。
- 中草药组DLQI改善优于安慰剂组(MD -2.12,95%CI -3.75至-0.49,p=0.01)。
核心结论
- 中草药治疗银屑病似乎安全有效,并对患者皮肤病生活质量指数有积极影响。
- 中草药不能完全消除皮损、改善瘙痒严重程度或降低复发率。
研究设计与样本
- 系统检索PubMed、Embase、Cochrane Central Register of Controlled Trials、中国知网、中国科技期刊数据库和万方数据库。
- 纳入比较中草药与非中草药干预的高质量随机对照试验,共1215例患者,实验组711例,对照组504例。
- 使用RevMan5.3软件计算95%置信区间的风险比(RR)并进行meta分析。
主要发现
- 中草药组PASI评分显著低于安慰剂组(MD -4.02,95%CI -6.71至-1.34,p=0.003)。
- 中草药组达到PASI-60的到达率高于安慰剂组(RR 3.52,95%CI 1.17至10.61,p=0.03)。
- 中草药组达到PASI-75的到达率高于安慰剂组(RR 9.87,95%CI 3.11至31.31,p=0.0001)。
- 中草药组有效率高于安慰剂组(RR 1.72,95%CI 1.01至2.93,p=0.04)。
- 中草药组DLQI改善优于安慰剂组(MD -2.12,95%CI -3.75至-0.49,p=0.01)。
临床怎么用
- 对于银屑病患者,中草药可作为改善皮损严重程度和生活质量的治疗选择。
- 应告知患者中草药不能完全消除皮损、改善瘙痒或降低复发率。
- 使用中草药时需关注不良事件,尽管比例与安慰剂相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Chinese herbal medicine (CHM) provides a theoretical basis for the treatment of psoriasis with considerable benefits and a low toxicity. The purpose of this quantitative study was to show high-quality evidence of the efficacy and safety of CHM for the treatment of psoriasis to promote its clinical application. Methods: Several databases were systematically searched including PubMed, Embase, Cochrane Central Register of Controlled Trials, China Network Knowledge Infrastructure, Chinese Scientific Journals Database, and Wan Fang Database. High-quality randomized controlled trials that compared CHM with non-CHM interventions were included. The RevMan5.3 software was used to calculate risk ratios (RR) at 95% confidence intervals (CI) and conduct the meta-analysis. Results: Altogether, 1,215 patients participated in this study, including 711 in the experimental group and 504 in the control group. The psoriasis area severity index (PASI) score of the CHM group was significantly lower than that of the placebo group (MD, -4.02; 95% CI, -6.71 to -1.34; p = 0.003). To achieve PASI-60 and PASI-75, the arrival rate of the CHM group was higher than that of the placebo group (PASI-60: RR, 3.52; 95% CI, 1.17 to 10.61; p = 0.03; PASI-75: RR, 9.87; 95% CI, 3.11 to 31.31; p = 0.0001). Furthermore, the efficacy rate was higher in patients receiving CHM than in those receiving placebo (RR, 1.72; 95% CI, 1.01 to 2.93; p = 0.04). The results suggested a greater impact of CHM in improving the dermatology life quality index (DLQI) of patients (MD, -2.12; 95% CI, -3.75 to -0.49; p = 0.01). Regarding pruritus severity, there was no significant difference between the two groups (MD, -1.90; 95% CI, -3.79 to -0.01; p = 0.05). The meta-analysis revealed that the recurrence rate (RR, 0.74; 95% CI, 0.32 to 1.71; p = 0.48) and proportion of adverse events (RR, 1.36; 95% CI, 0.95 to 1.93; p = 0.09) associated with using CHM were similar to those associated with using a placebo. Conclusion: CHM appears safe and effective in the treatment of psoriasis and has a great positive impact on the DQLI of patients; however, CHM could not completely eliminate skin lesions, improve pruritus severity, and reduce the recurrence rate.
引用
- Luo Y, Chen J, Kuai L, et al. Chinese Herbal Medicine for Psoriasis: Evidence From 11 High-Quality Randomized Controlled Trials. Front Pharmacol. 2021. PMID: 33551804. doi:10.3389/fphar.2020.599433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。